Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 6 min ago
Peer-reviewedCC BY-NCInfection & chemotherapy

Recommendations for Adult Pneumococcal Vaccination in Korea: 2026 Update Incorporating the 21-Valent Pneumococcal Conjugate Vaccine.

  • Joon Young Song1
  • Ki Tae Kwon2
  • Wan Beom Park3
  • Ji Yun Noh1
  • Sun Hee Park4
  • Eun Ju Choo5
  • Min Joo Choi1
  • Jun Yong Choi6
  • Jung Yeon Heo7
  • Won Suk Choi1
  • Committee of Adult Immunization in the Korean Society of Infectious Diseases
7 affiliations
  1. 1Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.
  2. 2Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Korea. [email protected].
  3. 3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  4. 4Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  5. 5Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, Soonchunhyang University of Korea, Bucheon, Korea.
  6. 6Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  7. 7Department of Infectious Diseases, Ajou University School of Medicine, Suwon, Korea.
Read full textPDFDOICite

Abstract

The 21-valent pneumococcal conjugate vaccine (PCV21; CAPVAXIVE; Merck Sharp & Dohme) is the first pneumococcal conjugate vaccine (PCV) specifically designed for adults, targeting serotypes that currently cause disease in this population. PCV21 includes 11 serotypes not contained in any other approved PCV (9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B), together with serotypes 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. PCV21 was approved by the Korean Ministry of Food and Drug Safety in August 27, 2025. The Adult Immunization Committee of the Korean Society of Infectious Diseases recommends one of the following options for all adults aged ≥65 years and for adults aged 19-64 years at increased risk of pneumococcal disease: a single dose of PCV21, a single dose of PCV20, or sequential PCV15 followed by PPSV23, with no stated preference among these options. When PCV21 or PCV20 is administered, no additional pneumococcal vaccination is required. Because PCV21 does not include serotype 4, in populations with a high incidence of serotype 4 disease, PCV20 alone or sequential PCV15 followed by PPSV23 may be preferentially considered.

Related

  1. Cost-effectiveness of 20-valent versus 15-valent pneumococcal conjugate vaccines for infants in the Netherlands, taking into account indirect effects and adult vaccination
    Pieter T. de Boer, Albert Jan van Hoek, Mirjam Knol +4
    BMC MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  2. Immunogenicity of sequential conjugate and non-conjugate pneumococcal vaccination in dialysis patients and kidney transplant recipients: a 12-month serological follow-up
    Sophie Novelli, Aimé Nun, Antoine Cases +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  3. Antimicrobial resistance trends and lineage distribution among invasive pneumococcal disease isolates pre- and post-pneumococcal conjugate vaccine introduction, South Africa
    Cebile Lekhuleni, Kedibone Ndlangisa, Linda de Gouveia +17
    Journal of InfectionPeer-reviewedCC BYFull textEpidemiology & public healthDOAJ
  4. Effectiveness of 20-valent pneumococcal conjugate vaccine against pneumococcal pneumonia hospitalizations among U.S. adults: Test-Negative Design
    A. J. Ologunowa, S. Kogut, V. L. Vrishali +2
    medRxivPreprintCC BYFull textInfectious diseasemedRxiv
  5. The Health and Economic Impact of the Adult-specific 21-valent (aPCV21) Pneumococcal Conjugate Vaccine vs PCV20 on Invasive Pneumococcal Disease Among Adults Aged 65 years in the United Kingdom: A Modeling Study
    P. P. Mueller, M. Simuzingili, I. R. Matthews +2
    medRxivPreprintCC BY-NDFull textInfectious diseasemedRxiv

Cite

BibTeXRIS
BibTeX
@article{song2026recommendations,
  title = {{Recommendations for Adult Pneumococcal Vaccination in Korea: 2026 Update Incorporating the 21-Valent Pneumococcal Conjugate Vaccine.}},
  author = {Joon Young Song and Ki Tae Kwon and Wan Beom Park and Ji Yun Noh and Sun Hee Park and Eun Ju Choo and Min Joo Choi and Jun Yong Choi and Jung Yeon Heo and Won Suk Choi and Committee of Adult Immunization in the Korean Society of Infectious Diseases},
  journal = {Infection \& chemotherapy},
  year = {2026},
  month = sep,
  doi = {10.3947/ic.2026.0063},
  url = {https://europepmc.org/article/MED/42847625},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Recommendations for Adult Pneumococcal Vaccination in Korea: 2026 Update Incorporating the 21-Valent Pneumococcal Conjugate Vaccine.
AU  - Joon Young Song
AU  - Ki Tae Kwon
AU  - Wan Beom Park
AU  - Ji Yun Noh
AU  - Sun Hee Park
AU  - Eun Ju Choo
AU  - Min Joo Choi
AU  - Jun Yong Choi
AU  - Jung Yeon Heo
AU  - Won Suk Choi
AU  - Committee of Adult Immunization in the Korean Society of Infectious Diseases
PY  - 2026
DA  - 2026/09/01
JO  - Infection & chemotherapy
DO  - 10.3947/ic.2026.0063
UR  - https://europepmc.org/article/MED/42847625
AB  - The 21-valent pneumococcal conjugate vaccine (PCV21; CAPVAXIVE; Merck Sharp & Dohme) is the first pneumococcal conjugate vaccine (PCV) specifically designed for adults, targeting serotypes that currently cause disease in this population. PCV21 includes 11 serotypes not contained in any other approved PCV (9N, 15A, 15C, 16F, 17F, 20A, 23A, 23B, 24F, 31, and 35B), together with serotypes 3, 6A, 7F, 8, 10A, 11A, 12F, 19A, 22F, and 33F. PCV21 was approved by the Korean Ministry of Food and Drug Safety in August 27, 2025. The Adult Immunization Committee of the Korean Society of Infectious Diseases recommends one of the following options for all adults aged ≥65 years and for adults aged 19-64 years at increased risk of pneumococcal disease: a single dose of PCV21, a single dose of PCV20, or sequential PCV15 followed by PPSV23, with no stated preference among these options. When PCV21 or PCV20 is administered, no additional pneumococcal vaccination is required. Because PCV21 does not include serotype 4, in populations with a high incidence of serotype 4 disease, PCV20 alone or sequential PCV15 followed by PPSV23 may be preferentially considered.
SN  - 2093-2340
SN  - 2092-6448
ER  -